HER2 and Src co-regulate proliferation, migration and transformation by downstream signaling pathways in arsenite-treated human uroepithelial cells.

Epidemiological studies have established a strong association between arsenic exposure in drinking water and an increased incidence of bladder cancer in arseniasis-endemic areas. Increased expression of HER2 has been observed in various types of human malignancies including bladder cancer. This study investigated the role of HER2 in arsenite-induced transformation of uroepithelial cells SV-HUC-1 and the role of Src family kinases in HER2 signaling. We found that the expression HER2 and Src were increased following chronic arsenite exposure in a time-dependent fashion. Chronic arsenite exposure also led to an upregulation of proliferation factors such as cyclin D1, COX2, PCNA, VEGF, and HIF-1α. Furthermore, Ras/Raf/MAPK, PI3K/AKT, and JAK2/STAT3 signaling pathways were activated by arsenite treatment. Importantly, these changes were inhibited by HER2 inhibitors and in HER2 knocked down cells. In addition, downregulation of HER2 inhibited cell growth and migration properties of arsenite-treated cells. Inhibition of Src also inhibits activation of signaling pathways and malignant transformation of cells. And we obtained evidence of an interaction between HER2 and Src in SV-HUC-1 cell lines. These results suggest that HER2 and Src may play an important role in arsenite-induced transformation by multiple downstream signals pathways.

[1]  Donglei Sun,et al.  N6-methyladenosine mediates the cellular proliferation and apoptosis via microRNAs in arsenite-transformed cells. , 2018, Toxicology letters.

[2]  Kazuhiro Yoshida,et al.  DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells , 2018, International journal of molecular sciences.

[3]  M. Cekanova,et al.  Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro , 2018, Drug design, development and therapy.

[4]  A. Hartmann,et al.  Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer , 2018, Translational oncology.

[5]  G. Packham,et al.  Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer. , 2017, Urology.

[6]  Zunzhen Zhang,et al.  MicroRNA-155 regulates arsenite-induced malignant transformation by targeting Nrf2-mediated oxidative damage in human bronchial epithelial cells. , 2017, Toxicology letters.

[7]  E. Silbergeld,et al.  The Association of Arsenic Metabolism with Cancer, Cardiovascular Disease, and Diabetes: A Systematic Review of the Epidemiological Evidence , 2017, Environmental health perspectives.

[8]  S. Garrett,et al.  The expression of keratin 6 is regulated by the activation of the ERK1/2 pathway in arsenite transformed human urothelial cells , 2017, Toxicology and applied pharmacology.

[9]  Shengnan Liu,et al.  Low concentration arsenite activated JAK2/STAT3 signal and increased proliferative factor expressions in SV‐HUC‐1cells after short and long time treatment , 2017, Environmental toxicology.

[10]  Inho Choi,et al.  Heavy Metals and Human Health: Mechanistic Insight into Toxicity and Counter Defense System of Antioxidants , 2015, International journal of molecular sciences.

[11]  A. Gračanin,et al.  High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression , 2015, BMC Cancer.

[12]  B. Molinari,et al.  Effect of Sodium Arsenite on Mouse Skin Carcinogenesis , 2015, Toxicologic pathology.

[13]  Wei Li,et al.  HIF-1α pathway: role, regulation and intervention for cancer therapy , 2015, Acta pharmaceutica Sinica. B.

[14]  F. Montemurro,et al.  Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. , 2015, Cell reports.

[15]  A. Laenkholm,et al.  Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment , 2015, PloS one.

[16]  Seung-Do Yu,et al.  Environmental Source of Arsenic Exposure , 2014, Journal of preventive medicine and public health = Yebang Uihakhoe chi.

[17]  L. Parker,et al.  Arsenic in drinking water and urinary tract cancers: a systematic review of 30 years of epidemiological evidence , 2014, Environmental Health.

[18]  A. Ahluwalia,et al.  VEGF and colon cancer growth beyond angiogenesis: does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism? , 2014, Current pharmaceutical design.

[19]  S. Boorjian,et al.  Expression of cyclin d1 and its association with disease characteristics in bladder cancer. , 2013, Anticancer research.

[20]  Fei Wang,et al.  Arsenic induces the expressions of angiogenesis-related factors through PI3K and MAPK pathways in SV-HUC-1 human uroepithelial cells. , 2013, Toxicology letters.

[21]  Habibul Ahsan,et al.  The Broad Scope of Health Effects from Chronic Arsenic Exposure: Update on a Worldwide Public Health Problem , 2013, Environmental health perspectives.

[22]  Jianping Zhang,et al.  Opposed arsenite-mediated regulation of p53-survivin is involved in neoplastic transformation, DNA damage, or apoptosis in human keratinocytes. , 2012, Toxicology.

[23]  M. Ladanyi,et al.  Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas , 2012, Clinical Cancer Research.

[24]  K. Blackwell,et al.  Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Radvanyi,et al.  Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  D. Hansel,et al.  HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. , 2008, American journal of clinical pathology.

[27]  M. Weinfeld,et al.  Attenuation of DNA damage‐induced p53 expression by arsenic: A possible mechanism for arsenic co‐carcinogenesis , 2008, Molecular carcinogenesis.

[28]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[29]  A. J. Gandolfi,et al.  Monomethylarsonous acid induces transformation of human bladder cells. , 2006, Toxicology and applied pharmacology.

[30]  G. Semenza,et al.  Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways , 2005, Oncogene.

[31]  A. Moinzadeh,et al.  The src‐family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt , 2005, BJU international.

[32]  P. Agostinis,et al.  Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy , 2005, Oncogene.

[33]  S. Courtneidge,et al.  The interplay between Src family kinases and receptor tyrosine kinases , 2004, Oncogene.

[34]  T. Yamaki,et al.  Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3. , 2004, Cancer letters.

[35]  Roy S Herbst,et al.  Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.

[36]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[37]  S. Garrett,et al.  Inorganic cadmium- and arsenite-induced malignant transformation of human bladder urothelial cells. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[38]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[39]  Y. Hsueh,et al.  Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. , 2003, Toxicology letters.

[40]  Kazuo T. Suzuki,et al.  Arsenic round the world: a review. , 2002, Talanta.

[41]  S. Parsons,et al.  Src family kinases and HER2 interactions in human breast cancer cell growth and survival , 2001, Oncogene.

[42]  A. Zuckerman,et al.  IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1995, IARC monographs on the evaluation of carcinogenic risks to humans.

[43]  L. Parker,et al.  Estimating the risk of bladder and kidney cancer from exposure to low-levels of arsenic in drinking water, Nova Scotia, Canada. , 2018, Environment international.

[44]  M. Karin,et al.  NF-κB and STAT3 – key players in liver inflammation and cancer , 2011, Cell Research.

[45]  B. Kos-Kudła,et al.  Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology. , 2011, Endokrynologia Polska.

[46]  David S. Paul,et al.  Metabolism of arsenic in human liver: the role of membrane transporters , 2009, Archives of Toxicology.

[47]  T. Hei,et al.  Neoplastic Transformation of Human Small Airway Epithelial Cells Induced by Arsenic , 2008, Molecular medicine.